-
Solriamfetol, sold
under the
brand name Sunosi, is a wakefulness-promoting
medication used in the
treatment of
excessive sleepiness related to narcolepsy...
-
medications include alerting agents (e.g., modafinil, armodafinil, pitolisant,
solriamfetol),
oxybate medications (e.g.,
twice nightly sodium oxybate,
twice nightly...
- of
solriamfetol at human, mouse, and rat TAAR1 receptors. hTAAR1 EC50
values (10–16 μM) were
within the
clinically observed therapeutic solriamfetol plasma...
- (Meretran)
Prolintane (Promotil, Katovit)
Pyrovalerone (Centroton, Thymergix)
Solriamfetol (Sunosi)
Tametraline (CP-24,411) WY-46824 Some NDRIs, such as methylphenidate...
- and well-balanced norepinephrine–dopamine
reuptake inhibitor (NDRI)
solriamfetol (brand name Sunosi; O-carbamoyl-D-phenylalaninol) is a
derivative of...
-
vanoxerine Norepinephrine–dopamine
reuptake inhibitors like methylphenidate,
solriamfetol, mazindol, bupropion, nomifensine, and
amineptine Norepinephrine–dopamine...
-
atypical DRIs with
known or
potential wakefulness-promoting
effects include solriamfetol (also a
norepinephrine reuptake inhibitor), vanoxerine, phenylpiracetam...
-
dopamine reuptake inhibitors include modafinil,
mesocarb (Sydnocarb), and
solriamfetol.
Phenylpiracetam binds to α4β2
nicotinic acetylcholine receptors in the...
- disease.
Phenylpiracetam Isopropylphenidate Rimcazole Venlafaxine (weak)
Solriamfetol (also
norepinephrine reuptake inhibitor)
Chaenomeles speciosa (Flowering...
- (January 7, 2020). "Schedules of
Controlled Substances:
Placement of
Solriamfetol in
Schedule IV".
Federal Register. Drug
Enforcement Administration. Retrieved...
